alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT 11.1

                          VACATION BREAK U.S.A., INC.
             STATEMENT REGARDING COMPUTATION OF PER SHARE EARNINGS
                        FOR THE YEAR ENDED DECEMBER 31,

                                                     1996               1995
                                             ---------------------   ---------
                                                          Fully
                                              Primary     Diluted    Proforma
                                             ---------   ---------   ---------

Actual number of common shares outstanding   8,593,724   8,593,724   8,300,000
                                             ---------   ---------   ---------
Weighted average number of common
  shares issued and outstanding              8,572,934   8,572,934   6,524,658
Common stock equivalents computed under
  the Treasury Stock method                    270,313     518,917           -
                                             ---------   ---------   ---------
                                             8,843,247   9,091,851   6,524,858
                                             ---------   ---------   ---------
Net income                                  $7,239,715  $7,239,715  $5,845,455
                                             ---------   ---------   ---------
Net income per share                        $     0.82  $     0.80  $     0.90
                                             ---------   ---------   ---------
|   1. |                The quarterly report of the Company for the period ended September 30, 2010 as filed with the Securities and Exchange Commission on this date (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   2. |                The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Date:   November 12, 2010 | By:                           | /s/ Brandon Cade Thompson |
|------------------------------------------|-------------------------------|---------------------------|
|                                     | Brandon Cade Thompson         |
|                                     | Chief Executive Officer       |
|                                     | (Principal Executive Officer) |
|                                     |                          |
| Date:   November 12, 2010 | By:                           | /s/ Paul Williams         |
|                                     | Paul Williams                 |
|                                     | Chief Financial Officer       |
|                                     | (Principal Financial Officer) |

----
d'opci6n del:Plan; 

D)'consideraca la 

los I Fondados de 

utter. " 

e'Limpio de'1997 

[ el avance=de la 

ael de calidad' del 

uestos de emisiori 

a'dopt"ar y ejecutar 

~ vNx tomaran en 

de 2009. NOTAi 

D " `considerara' la 

iajo.`El Plan?y el' 

SMAQMD'en 

diciembre, 2008: 

sa del Pian;y del 

todas las partes 

imonibs orales o 

bhcas„o engiarsel 

I am the principal clerk of the EL HISPANO, a newspaper of 

general circulation published in the City of Sacramento, County 

of Sacramento, and which newspaper has been adjudged a newspaper of general circulation by the Superior Court of the County P 

of Sacramento, State of Califomia, under date of October 8,1968, 

Case Number205413. The notice, ofwhichthe annexed is aprinted 

copy, has been published in each regular and entire issue of saidLos distritos proi 

newspaper and not in any supplement thereof on the following llevaran a- c,abo'.; 

Regional de Ozox 

dates, to wit: 12/24/08 ". 'ul' TliaMiin -TiTuf.iR 

I certify (or declare) under penalty of perjury that the foregoing 

is tme and correct. EI plar triuesfra que la-reg 

sobre la norma d'e `emi'sii 

reduccl6n d'e'la emtsiori i 

aire El Plan fambtEn actu 

para'el trarispotte y"de°e'oi 

Signature n'uevas medidas` de co'n'£ro 

Dated: 12/24/08 

El Hispano 

P.O. BO% 2856 

SACRAMENTO, CA 95812 

Mail Proof of Publication to: 

A 95814 

SMAQMD 

777 12th Street 3rd Floor 

Sacramento, CA 95814 

\.95618 , . 

r
# C_2014388EN.01002201.xml

| 3.11.2014 | EN | Official Journal of the European Union | C 388/22 |
| --- | --- | --- | --- |

3.11.2014

EN

Official Journal of the European Union

C 388/22

---

Action brought on 11 September 2014 — Peri v OHIM (Shape of a formwork coupler)

(Case T-656/14)

2014/C 388/27

Language of the case: German

Parties

Parties

Applicant: Peri GmbH (Weißenhorn, Germany) (represented by A. Bognár and M. Eck, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Defendant:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | Annul the decision of the First Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 26 June 2014 in Case R 1178/2013-1; |
| --- | --- |

—

Annul the decision of the First Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 26 June 2014 in Case R 1178/2013-1;

| — | Order the Office for Harmonisation in the Internal Market (Trade Marks and Designs) to pay the costs. |
| --- | --- |

—

Order the Office for Harmonisation in the Internal Market (Trade Marks and Designs) to pay the costs.

Pleas in law and main arguments

Pleas in law and main arguments

Community trade mark concerned: The three-dimensional mark in the shape of a formwork coupler for goods in Classes 6 and 19 — Community trade mark application No 1 0 8 26  766

Community trade mark concerned:

Decision of the Examiner: The application was rejected

Decision of the Examiner:

Decision of the Board of Appeal: The appeal was dismissed

Decision of the Board of Appeal:

Pleas in law:

Pleas in law:

| — | Infringement of Article 7(1)(e) of Regulation No 207/2009 |
| --- | --- |

—

Infringement of Article 7(1)(e) of Regulation No 207/2009

| — | Infringement of Article 7(1)(b) of Regulation No 207/2009 |
| --- | --- |

—

Infringement of Article 7(1)(b) of Regulation No 207/2009

---
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.2900 Automated urinalysis system. ( a ) *Identification.* An automated urinalysis system is a device intended to measure certain of the physical properties and chemical constituents of urine by procedures that duplicate manual urinalysis systems. This device is used in conjunction with certain materials to measure a variety of urinary analytes.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2309, Jan. 14, 2000]
**Exhibit 34.2**

 

**Report of Independent Registered Public Accounting Firm**

 

The Board of Directors

Citibank, N.A.:

 

We have examined management’s assessment, included in the accompanying Management’s Assessment of Compliance, that the Agency and Trust division of Citibank, N.A. (the “Company”) complied with the servicing criteria set forth in Item 1122(d) of the Securities and Exchange Commission’s Regulation AB for publicly-issued (i.e., transaction-level reporting initially required under the Securities Exchange Act of 1934, as amended) equipment loan-backed securities issued by CNH Equipment Trust, as listed in Appendix A of the accompanying Management’s Assessment of Compliance, for which the Company provides trustee and paying agent services (the “Platform”), except for servicing criteria 1122(d)(1)(i)-1122(d)(1)(v), 1122(d)(2)(iii), 1122(d)(2)(vi)-1122(d)(2)(vii), 1122(d)(3)(i) and 1122(d)(4)(i)-1122(d)(4)(xv), which the Company has determined are not applicable to the activities it performs with respect to the Platform, as of and for the twelve months ended December 31, 2015. With respect to the Platform, servicing criterion 1122(d)(3)(ii) is applicable only as it relates to remittances. Management is responsible for the Company’s compliance with the servicing criteria. Our responsibility is to express an opinion on management’s assessment about the Company’s compliance based on our examination.

 

Our examination was conducted in accordance with the attestation standards of the Public Company Accounting Oversight Board (United States) and, accordingly, included examining, on a test basis, evidence about the Company’s compliance with the servicing criteria specified above and performing such other procedures as we considered necessary in the circumstances. Our examination included testing selected asset-backed transactions and securities that comprise the Platform, testing selected servicing activities related to the Platform, and determining whether the Company processed those selected transactions and performed those selected activities in compliance with the servicing criteria. Furthermore, our procedures were limited to the selected transactions and servicing activities performed by the Company during the period covered by this report. Our procedures were not designed to determine whether errors may have occurred either prior to or subsequent to our tests that may have affected the balances or amounts calculated or reported by the Company during the period covered by this report for the selected transactions or any other transactions. We believe that our examination provides a reasonable basis for our opinion. Our examination does not provide a legal determination on the Company’s compliance with the servicing criteria.

 

In our opinion, management’s assessment that the Company complied with the aforementioned servicing criteria as of and for the twelve months ended December 31, 2015 is fairly stated, in all material respects.

 

/s/KPMG LLP

 

Chicago, Illinois

February 26, 2016

 

----
[Federal Register Volume 75, Number 44 (Monday, March 8, 2010)]
[Notices]
[Page 10491]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4840]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Eunice Kennedy Shriver National Institute of Child Health & Human 
Development; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Child Health and Human 
Development Special Emphasis Panel Medical Rehabilitation Research 
Resource.
    Date: March 26, 2010.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Legacy Hotel and Meeting Center, 1775 Rockville Pike, 
Rockville, MD 20852.
    Contact Person: Anne Krey, Scientific Review Officer, Division 
of Scientific Review, Eunice Kennedy Shriver National Institute, of 
Child Health and Human Development, National Institutes of Health, 
Bethesda, MD 20892, 301-435-6908.

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, 
Population Research; 93.865, Research for Mothers and Children; 
93.929, Center for Medical Rehabilitation Research; 93.209, 
Contraception and Infertility Loan Repayment Program, National 
Institutes of Health, HHS)

    Dated: March 1, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-4840 Filed 3-5-10; 8:45 am]
BILLING CODE 4140-01-P
#### Anna M. Irish *v.*Howard S. Ives, Highway Commissioner

Kins, C. J., Alcorn, House, Thim and Shapiro, Js.

Argued March 11

decided April 1, 1969

*Robert L. Trowbridge,*with whom, on the brief, was *Richard Goodman,*for the appellant (defendant).

*William J. Shea, Jr.,*with whom, on the brief, was *John D. LaBelle,*for the appellee (plaintiff).

Alcorn, J.

The plaintiff recovered a verdict for injuries sustained as a result of a fall on an allegedly defective highway. The defendant has appealed from the judgment, assigning error in the denial of his motion to set aside the verdict, in the charge, and in a ruling on evidence.

The defect was described as a break in the edge of the asphalt pavement of a road which was under *117the jurisdiction and control of the defendant. The break was about three and one-half feet long, one and one-half feet wide, and two and one-half inches deep. There was no claim or proof that the defendant had actual knowledge of the break and no proof as to the length of time the break had existed. To recover under General Statutes § 13a-144, it was necessary for the plaintiff to prove either that the defendant had actual notice of the defect or that the defect had existed for such a length of time that it would have been known in the exercise of reasonable care and a reasonable opportunity would have been afforded in which to remedy it. *Shirlock*v. *MacDonald,*121 Conn. 611, 613, 186 A. 562; *Falkowski*v. *MacDonald,*116 Conn. 241, 243, 164 A. 650. Since the plaintiff failed to meet this essential element in her proof, the verdict cannot be supported.

It is unnecessary to discuss the other assignments of error.

There is error, the judgment is set aside and the case is remanded with direction to grant the motion to set the verdict aside.

In this opinion the other judges concurred.
Editorial Note on Part 890
Editorial Note: Nomenclature changes to part 890 appear at 73 FR 35341, June 23, 2008.

§ 890.1385 Diagnostic electromyograph needle electrode. ( a ) *Identification.* A diagnostic electromyograph needle electrode is a monopolar or bipolar needle intended to be inserted into muscle or nerve tissue to sense bioelectrical signals. The device is intended for medical purposes for use in connection with electromyography (recording the intrinsic electrical properties of skeletal muscle).
( b ) *Classification.* Class II (performance standards).
EXHIBIT 24

                                POWER OF ATTORNEY

The undersigned directors and officers of R-Tec Technologies, Inc. hereby
constitute and appoint Philip Lacqua, with full power to act without the other
and with full power of substitution and resubstitution, our true and lawful
attorney-in-fact with full power to execute in our name and behalf in the
capacities indicated below any and all amendments (including post-effective
amendments and amendments thereto) to this registration statement under the
Securities Act of 1933 and to file the same, with all exhibits thereto and other
documents in connection therewith, with the Securities and Exchange Commission
and hereby ratify and confirm each and every act and thing that such
attorney-in-fact, or his substitute, shall lawfully do or cause to be done by
virtue thereof. Pursuant to the requirements of the Securities Act of 1933, this
registration statement has been signed by the following persons in the
capacities and on the dates indicated.


----------------------------------------------------
Nancy Vitolo, Vice President, Secretary and Director

Date:  October 10, 2001
#### § 71.4 Samples; additional information.

The Commissioner may request samples of the color additive, articles used as components thereof, or of the food, drug, or cosmetic in which the color additive is proposed to be used, or which comprises the color additive, and any additional information needed to clarify a submitted method or other aspect of a petition at any time while a petition is under consideration. The Commissioner shall specify in the request for a sample of the color additive, or articles used as components thereof, or of the food, drug, or cosmetic in which the color additive is proposed to be used, or which comprises the color additive, a quantity deemed adequate to permit tests of analytical methods to determine quantities of the color additive present in products for which it is intended to be used or adequate for any study or investigation reasonably required with respect to the safety of the color additive or the physical or technical effect it produces. The date used for computing the 90-day limit for the purposes of section 721(d)(1) of the act shall be moved forward 1 day for each day, after mailing date of the request, taken by the petitioner to submit the information and/or sample. If the information or sample is requested a reasonable time in advance of the 180 days, but is not submitted within such 180 days after filing of the petition, the petition will be considered withdrawn without prejudice.
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.5310 Intranasal electrostimulation device for dry eye symptoms. ( a ) *Identification.* An intranasal electrostimulation device for dry eye symptoms is a prescription non-implantable, electrostimulation device intended to increase tear production for improvement in dry eye symptoms.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Clinical performance testing must evaluate improvement of dry eye symptoms under anticipated conditions of use.
( 2 ) Non-clinical performance testing must assess the following electrical output specifications: waveforms, output modes, maximum output voltage, maximum output current, pulse duration, frequency, net charge per pulse, maximum phase charge at 500 ohms, maximum current density, maximum average current, and maximum average power density.
( 3 ) Patient-contacting components of the device must be demonstrated to be biocompatible.
( 4 ) Performance testing must demonstrate the electrical, thermal, and mechanical safety along with electromagnetic compatibility (EMC) of the device in the intended use environment.
( 5 ) Software verification, validation, and hazard analysis must be performed.
( 6 ) Training for the proper use of the device must be provided.
( 7 ) Physician and patient labeling must include: ( i ) Summaries of electrical stimulation parameters;
( ii ) Instructions on how to correctly use and maintain the device;
( iii ) Instructions and explanations of all user-interface components;
( iv ) Information related to electromagnetic compatibility classification;
( v ) Instructions on how to clean the device; and
( vi ) Summaries of clinical performance testing demonstrating safety and effectiveness.
[83 FR 52975, Oct. 19, 2018]
Exhibit 31.2



CERTIFICATION OF PRINCIPAL FINANCIAL
OFFICER

PURSUANT TO

SECTION 13(a) OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT
OF 2002



I, Lawrence A. Kenyon, certify that:



| | 1. | I have reviewed
                                         this Amendment No. 1 to the Annual Report on Form 10-K of Oncobiologics, Inc.
                                         (the “registrant”); and
| | -- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | 2. | Based on my
                                         knowledge, this report does not contain any untrue statement of a material fact or omit
                                         to state a material fact necessary to make the statements made, in light of the circumstances
                                         under which such statements were made, not misleading with respect to the period covered
                                         by this report.
| | -- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



Date: January 27, 2017



|/s/ Lawrence A. Kenyon  | 
|----------------------- | 
|Lawrence A. Kenyon      | 
|Chief Financial Officer |
#### § 820.22 Quality audit.

Each manufacturer shall establish procedures for quality audits and conduct such audits to assure that the quality system is in compliance with the established quality system requirements and to determine the effectiveness of the quality system. Quality audits shall be conducted by individuals who do not have direct responsibility for the matters being audited. Corrective action(s), including a reaudit of deficient matters, shall be taken when necessary. A report of the results of each quality audit, and reaudit(s) where taken, shall be made and such reports shall be reviewed by management having responsibility for the matters audited. The dates and results of quality audits and reaudits shall be documented.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS FINANCIAL INFORMATION EXTRACTED FROM THE UNAUDITED JUNE
30, 1998 FINANCIAL STATEMENTS AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          MAR-31-1999
<PERIOD-START>                             APR-01-1998
<PERIOD-END>                               JUN-30-1998
<CASH>                                         764,613
<SECURITIES>                                         0
<RECEIVABLES>                                  392,537
<ALLOWANCES>                                    78,178
<INVENTORY>                                          0
<CURRENT-ASSETS>                             1,205,946
<PP&E>                                       1,940,535
<DEPRECIATION>                               1,464,299
<TOTAL-ASSETS>                               2,226,027
<CURRENT-LIABILITIES>                        1,127,249
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        32,184
<OTHER-SE>                                   9,206,043
<TOTAL-LIABILITY-AND-EQUITY>                 2,226,027
<SALES>                                        846,137
<TOTAL-REVENUES>                             1,199,710
<CGS>                                                0
<TOTAL-COSTS>                                  239,896
<OTHER-EXPENSES>                               822,703
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              22,043
<INCOME-PRETAX>                                116,048
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            116,048
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   116,048
<EPS-PRIMARY>                                      .04
<EPS-DILUTED>                                      .03
        

</TABLE>